Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Altmann

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 17, 2022
Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trialLisa Voggenberger, Marion Böck, Doris Moser, et al.
European Journal of Neurology|November 4, 2020
Longitudinal measurement of cerebrospinal fluid neurofilament light in anti-N-methyl-D-aspartate receptor encephalitisStefan Macher, Tobias Zrzavy, Romana Höftberger, et al.
Digital Health|July 18, 2022
Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trialPatrick Altmann, Fritz Leutmezer, Markus Ponleitner, et al.
Frontiers in Neurology|March 24, 2022
Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple SclerosisNik Krajnc, Patrick Altmann, Katharina Riedl, et al.
Acta Neurologica Scandinavica|November 18, 2018
Do elevated autoantibodies in patients with multiple sclerosis matter?Assunta Dal-Bianco, Fritz Wenhoda, Paulus Stefan Rommer, et al.
International Journal of Environmental Research and Public Health|January 21, 2022
Individual Perception of Telehealth: Validation of a German Translation of the Telemedicine Perception Questionnaire and a Derived Short VersionPatrick Altmann, Dominik Ivkic, Markus Ponleitner, et al.
Digital Health|February 6, 2025
Cost-effectiveness of the Floodlight<sup>®</sup> MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosisEvelyn Walter, Matthäus Traunfellner, Franz Meyer, et al.
Scientific Reports|October 3, 2024
Investigation of serum neurofilament light chain as a biomarker in Fabry diseaseMarkus Ponleitner, Constantin Gatterer, Gabriel Bsteh, et al.
Journal of Neurology|September 15, 2020
Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosisTobias Monschein, Sabine Salhofer-Polanyi, Patrick Altmann, et al.
Wiener Klinische Wochenschrift|April 22, 2025
A randomized controlled pilot study investigating adherence to blood pressure diaries with personal pictures in stroke follow-up careClemens V Farr, Johanna Ebner, Marie Beatrice Lang, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 17, 2022
Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trialLisa Voggenberger, Marion Böck, Doris Moser, et al.
European Journal of Neurology|November 4, 2020
Longitudinal measurement of cerebrospinal fluid neurofilament light in anti-N-methyl-D-aspartate receptor encephalitisStefan Macher, Tobias Zrzavy, Romana Höftberger, et al.
Digital Health|July 18, 2022
Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trialPatrick Altmann, Fritz Leutmezer, Markus Ponleitner, et al.
Frontiers in Neurology|March 24, 2022
Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple SclerosisNik Krajnc, Patrick Altmann, Katharina Riedl, et al.
Acta Neurologica Scandinavica|November 18, 2018
Do elevated autoantibodies in patients with multiple sclerosis matter?Assunta Dal-Bianco, Fritz Wenhoda, Paulus Stefan Rommer, et al.
International Journal of Environmental Research and Public Health|January 21, 2022
Individual Perception of Telehealth: Validation of a German Translation of the Telemedicine Perception Questionnaire and a Derived Short VersionPatrick Altmann, Dominik Ivkic, Markus Ponleitner, et al.
Digital Health|February 6, 2025
Cost-effectiveness of the Floodlight<sup>®</sup> MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosisEvelyn Walter, Matthäus Traunfellner, Franz Meyer, et al.
Scientific Reports|October 3, 2024
Investigation of serum neurofilament light chain as a biomarker in Fabry diseaseMarkus Ponleitner, Constantin Gatterer, Gabriel Bsteh, et al.
Journal of Neurology|September 15, 2020
Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosisTobias Monschein, Sabine Salhofer-Polanyi, Patrick Altmann, et al.
Wiener Klinische Wochenschrift|April 22, 2025
A randomized controlled pilot study investigating adherence to blood pressure diaries with personal pictures in stroke follow-up careClemens V Farr, Johanna Ebner, Marie Beatrice Lang, et al.
Pageof 6